Peijia Medical reports record growth with 46% surge in heart valve implants

Peijia Medical has reported a strong fiscal year, with rising demand across its key product lines. The company's expansion into more hospitals and recent regulatory approvals have set the stage for further growth in 2026.

The firm now serves over 780 medical facilities after adding around 130 new hospitals to its network.

Revenue growth was driven by two main areas: heart valve therapies and neurovascular products. In the structural heart disease segment, transcatheter aortic valve replacement (TAVR) procedures surged, with 5,247 implants in 2024—a 46% jump from the previous year's 3,592. This segment alone saw a 14.4% increase, reaching about 3,900 implants.

Neurovascular products also performed well, with high demand for specialised tools like the DCwire micro gold wire and the Syphonet stent retriever. Another boost came from the recent NMPA approval of the TaurusTrio system, allowing Peijia Medical to enter the aortic insufficiency news and capture new share.

Looking ahead, the company expects 2025 revenue to hit between 700 million and 720 million RMB, marking a 14% to 17% rise. The second half of 2026 will be pivotal, as regulators review next-generation products like TaurusNXT and GeminiOne. Final profitability figures will be confirmed in March 2026 when audited results are released.

Peijia Medical's expansion and regulatory milestones position it for continued growth in specialised medical markets. The company's focus on heart valve and neurovascular therapies has already delivered strong results, with further gains expected as new products reach approval.